Jul 13, 2020 / 12:15PM GMT
Operator
Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the Ovid Therapeutics conference call. (Operator Instructions)
It is now my pleasure to turn the call over to Jeff Rona, consulting CFO of Ovid Therapeutics. Please go ahead, sir.
Jeffrey Rona;Consulting CFO -
Thank you, operator, and thank you, everyone, for dialing in today.
Earlier this morning, Ovid announced an exclusive license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of Angelman syndrome in Europe. The press release can be found on Ovid's website at www.ovidrx.com.
Please note that we will have webcast slides to accompany this call. For those dialing in, it may be helpful to go to the Investors page of our website and access the webcast player now if you haven't done so already. A PDF of the webcast slides will also be made available.
Joining me on the call this morning are Dr. Jeremy Levin, Ovid's Chairman and Chief
Ovid Therapeutics Inc. - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot